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Abstract
Background. Vitamin D is a compound of great importance in controlling the biological functions of the body in 
a variety of ways. Significance of vitamin D in the pathogenesis and treatment of various diseases has been described 
repeatedly. One of the most discussed issues in the literature is the importance of vitamin D deficiency in the patho-
genesis of hypertension. This relationship is particularly important in patients burdened with elevated cardiovascular 
risk, which undoubtedly represent patients with diagnosed disease of the cardiovascular system. The aim of the study 
was to determine the association between the occurrence of vitamin D deficiency and the prevalence of hypertension 
in premenopausal women at very high cardiovascular risk.
Materials and methods. The study included 49 women who had previously been diagnosed with cardiovascular 
disease. In all patients enrolled in the study serum concentrations of vitamin D were measured and the patients were 
classified to have vitamin D deficiency or normal vitamin D level, based on the existing criteria. The patients were 
also tested for the occurrence of hypertension. Medical records of all patients were reviewed for early diagnosis of 
hypertension, and blood pressure measurements were performed on admission to the hospital before the surgery by 
a qualified physician, in a manner consistent with current guidelines 
Results. The study population was aged 47.7 ± 13.4 years. The mean body mass index was 25.2 kg/m2. Vitamin D 
deficiency was diagnosed in 25 (51%) patients, and hypertension was diagnosed in 30 women (61.2%). In patients 
with vitamin D deficiency hypertension occurred in 18 (72%) women, while in the group without vitamin D 
deficiency hypertension was diagnosed in 50% of cases (12 women). The observed difference between the groups 
was statistically significant (p = 0.049). There was no difference in the incidence of other cardiovascular risk factors 
between the groups, including the prevalence of dyslipidaemia or nicotine addiction.
Conclusion. Association of hypertension with the vitamin D deficiency has been repeatedly underlined in many 
scientific studies. In the present group of patients at very high cardiovascular risk, we confirmed the relationship of 
vitamin D deficiency with the occurrence of hypertension. Exact confirmation of this issue requires further, large-
scale research, but this study may suggest the importance of vitamin D supplementation in these patients.
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Introduction
Vitamin D is lipid soluble prohormone synthe-
sised in the skin after exposure to sunlight. It can be 
also delivered with food. Vitamin D in its active form 
has lots of differentiated effects, which include influ-
encing bone and muscle metabolism as well as con-
trol of other vital mechanisms. More and more find-
ings from various areas of medicine are published, 
e.g. dermatological use of vitamin D — in patients 
with systemic lupus erythematosus [1], patients with 
melanoma [2], endocrinology — levels of vitamin D 
are connected with the risk of diabetes type 2 and 
obesity [3]. Moreover, sufficient level of vitamin D 
is important for proper embryo implantation, tro-
phoblast invasion and angiogenesis during preg-
nancy [4]. Cardiovascular impact of this substance 
is debated. In the cardiovascular system vitamin D 
plays crucial role in renin-angiotensin-aldosterone 
system activation, which leads to the development 
of one of the most widespread diseases — arterial 
hypertension (HTN). HTN affects over 1 billion 
people worldwide and large portion of this group are 
women [5]. HTN is not only a widespread disease, 
it is also a risk factor for further cardiovascular con-
sequences. Therefore, current study aims to describe 
whether vitamin D levels play important role in the 
development of hypertension in women with cardio-
vascular disease.
Material and methods
Study population
This was a prospective, observational cohort study 
performed in order to establish the prevalence of 
arterial hypertension in consecutive patients at very 
high cardiovascular risk screen in a tertiary Univer-
sity Hospital.
The study was conducted with respect to the De-
claration of Helsinki and an approval form the Ethics 
Committee by the Medical University of Warsaw was 
obtained before the beginning of the study. Written, 
informed consent was obtained from every study 
participant prior to the study enrolment.
The study cohort consisted of premenopausal 
consecutive female patients whose “very-high CVD 
risk” status was established with respect to the cur-
rent guidelines. Criteria for very high risk included: 
documented CVD, clinical or unequivocal on imag-
ing (includes previous myocardial infarction, acute 
coronary syndrome, coronary revascularization and 
other arterial revascularization procedures, stroke 
and transient ischaemic attack, aortic aneurysm and 
peripheral artery disease); diabetes mellitus with tar-
get organ damage such as proteinuria or with a major 
risk factor such as smoking or marked hypercholes-
terolaemia or marked hypertension; severe chronic 
kidney disease; or a calculated SCORE ≥ 10%. In all 
patients enrolled in the study, serum concentrations 
of vitamin D were measured and patients were clas-
sified to have or not have the vitamin D deficiency, 
based on the existing criteria.
Patients were recruited into the study between 
2015 and 2016. The study population consisted only 
of patients in whom the medical records allowed 
valid assessment of blood pressure values and current 
medical treatment. Exclusion criteria were: age < 
18 or ≥ 55 years, myocardial infarction, stroke or 
decompensation of heart failure within the last six 
months and absence of written informed consent. 
Data on demographics, lifestyle, comorbidity and 
cardiovascular risk factors were obtained. Demo-
graphic variables were analysed included age and 
sex. Comorbidities studied included presence or ab-
sence of heart failure, diabetes mellitus, stroke or TIA 
episodes, myocardial infarction episodes, peripheral 
artery disease, dyslipidaemia, coronary artery disease, 
important valvular defect, asthma, chronic obstruc-
tive pulmonary disease, CABG, PCI, cardiac pace-
maker implanted. All patients were also screened for 
other classical and non-classical cardiovascular risk 
factors including diabetes mellitus, dyslipidaemia, 
or history of cardiovascular disease. Diagnosis of all 
factors was made based on eligible medical records, 
taking prescription drugs applicable for the respec-
tive disease (i.g. hypoglycaemic agents for diabetes), 
or as a de novo diagnosis according to the current 
diagnostic criteria.
Screening for arterial hypertension
All study participants were screened for HTN. 
Patients had their blood pressure measured on ad-
mission by a qualified physician. Diagnosis of arterial 
hypertension was made when office blood pressure 
was equal or exceeded the values of 140 for systolic 
blood pressure (SBP) and/or 90 for diastolic blood 
pressure (DBP). The number of required measure-
ments, measurement techniques and settings were 
in accordance with the current guidelines for arterial 
hypertension diagnosis and management of the Eu-
ropean Society of Cardiology and European Society 
of Hypertension. The diagnosis was also made where 
there were eligible medical records available on pre-
vious diagnosis of arterial hypertension or taking 
prescription hypotensive agents.
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Laboratory testing
Blood samples were collected after hospitaliza-
tion before surgery, after a 20-minute rest following 
12 hours of fasting. Due to long half-life, serum 
25 hydroxy (OH) vitamin D was preferred instead of 
1,25 dihydroxy vitamin D. As serum 25(OH) vitamin 
D levels show a seasonal variability, in order to ob-
tain standard measurements, only patients who were 
operated in fall and winter seasons were examined. 
Serum 25(OH) D levels were measured by direct 
chemiluminescence immunoassay (Elecsys; Roche 
Diagnostics, Mannheim, Germany) method. Vita-
min D deficiency was defined as levels ≤ 20 ng/mL. 
Intra- and inter-assay coefficients of variation (CVs) 
were below 4.5% and 7.6%, respectively.
Statistical analysis
Statistical analysis was performed using the SAS soft-
ware version 8.02 (SAS Institute, Inc., Cary, NC, USA). 
Continuous data are presented as mean ± standard de-
viation (SD) and were compared using the Mann-Whit-
ney test or Student’s t-test. Categorical variables were 
compared using either the c2 or Fisher’s exact tests. 
A p value of less than 0.05 was considered statistically sig-
nificant, whereas the confidence intervals (CI) were 95%.
Results
The study population was aged 47.7 ± 13 4 years. 
The mean body mass index was 25.2 kg/m2. Vitamin 
D deficiency was diagnosed in 25 (51%) patients. In 
contrast, hypertension was diagnosed in 30 women 
(61.2%). The second most prevalent risk factor in 
this group of patients was dyslipidaemia (44.9% 
of patients), with the mean LDL cholesterol level 
of 109.1± 46.8 mg/dL. In the current population, 
premenopausal, very high CVD-risk patients often 
suffered from overweight (34.7%) and were current 
smokers (42.9%) (Table I).
After dividing the patients according to the vi-
tamin D levels, we observed following trends. In 
patients with vitamin D deficiency hypertension 
occurred in 18 (72%) women, while in the group 
without deficiency hypertension was diagnosed in 
50% of cases (12 women). The observed difference 
between the groups was statistically significant (p = 
0.049). There was no difference in the incidence of 
other cardiovascular risk factors between the groups, 
including the prevalence of dyslipidaemia or nicotine 
addiction (Table II, Figure 1). Interestingly, we also 
found that in patients without vitamin D deficiency 
Table I. Baseline characteristics of the study population
Parameter n (%) or mean ± SD Value
Age (years) 47.7 ± 13.4
Arterial hypertension 30 (61.2%)
Dyslipidaemia 22 (44.9%)
LDL-cholesterol level [mg/dL] 109.1 ± 46.8
Smoking 21 (42.9%)
Overweight 17 (34.7%)
BMI [kg/m2] 25.2 ± 5.9
Vitamin D deficiency [≤ 20 ng/mL] 25 (51.0%)
Vitamin D level [ng/mL] 109.1 ± 9.4 Figure 1. Prevalence of arterial hypertension according to the vitamin D levels
Table II. Characteristics of the group with and without vitamin D deficiency
Parameter n (%) or mean ± SD Patients without vitamin D 
deficiency (n = 24)
Patients with vitamin D  
deficiency (n = 25)
p value
Arterial hypertension 12 (50.0%) 18 (72.0%) 0.049
Dyslipidaemia 7 (29.2%) 15 (60.0%) 0.03
LDL-cholesterol level [mg/dL] 104.7 ± 37.7 113.0 ± 54.1 0.29
Smoking 12 (50.0%) 9 (36.0%) 0.24
Overweight 9 (37.5%) 8 (32.0%) 0.46
BMI [kg/m2] 26.4 ± 6.2 24.3 ± 5.7 0.21
Vitamin D level [ng/mL] 28.1 ± 7.0 11.4 ± 3.9 < 0.001
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there was a lower prevalence of dyslipidaemia (29.2 
vs. 60.0%; p = 0.03) (Figure 2).
Additional analysis comparing baseline character-
istics of patients with and without diagnosed HTN 
was also performed (Table III), but no significant 
differences between the groups were found.
Discussion
HTN is one of the most important risk factors 
for cardiovascular disease (CVD) [6]. It is estimated, 
that by 2025 the number of people with HTN will 
grow up to 1.56 billion [7]. This is one of the reasons 
why there is such desire to understand this illness as 
much in detail as possible. One of the new factors 
connected with HTN is vitamin D serum levels. 
More people are being diagnosed with HTN 
during winter, and living in higher latitudes [8]. This 
leads to hypothesis that vitamin D deficiency may be 
connected with HTN. This concept has been tested 
in lots of clinical trials. However, the outcomes are 
inconsistent. Some trials showed connection between 
25(OH)D serum level and blood pressure (BP), and 
some didn’t. Moreover, other trials showed that vi-
tamin D levels are associated with development and 
course of not only HTN but also other CVDs in-
cluding coronary heart disease  and heart failure 
[9–12].
One of the first clinical trials that were supposed to 
find connection between vitamin D level and HTN 
was made in 1988. It was a placebo-controlled trial 
which evaluated the effect of vitamin D analogue 
on BP. All the patients were hypertensive and had 
impaired glucose tolerance (mean age 62, n = 26). 
Significant reduction in both systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) was found 
from 171/95 to 150/88 mm Hg [13].  Another early 
trial was performed by Krause et al. who assessed 
patients with untreated mild HTN and vitamin D 
deficiency, who were later treated with UVB radia-
tion. The study showed increase in 25(OH)D level 
associated with BP reduction [14]. Both mentioned 
studies raised huge interest among researchers, which 
lead to lots of trials performed. As the effect, we have 
many meta-analyses now. One of them included 
283 537 non-overlapping participants and 55 816 
patients with HTN. Authors suggested, that every 
10 ng/mL increase in blood vitamin D level reduces risk 
of HTN by 12% [15]. Another meta-analysis of four 
controlled trials made by Wu et al. showed significant 
reduction in SBP (–2,44 mm Hg) without reduction 
of DBP [16] in hypertensive population. Another 
randomized, double-blind, placebo-controlled trial 
in Denmark was performed during winter. The au-
thors checked the effect of 3000 IU/day vitamin D 
supplementation on BP in hypertensive patients. The 
biggest decrease in BP was observed in patients with 
25(OH)D deficiency at the beginning of the trial [17]. 
This finding suggests that high-dose vitamin D supple-
mentation is more effective in hypertensive popula-
tion, and that vitamin D deficiency may be connec-
ted with HTN. 
Unfortunately, not every trial can lead to a strong 
conclusion. A placebo-controlled, randomized trial 
Table III. Characteristics of the group with and without arterial hypertension
Parameter n (%) or mean ± SD Patients without arterial 
hypertension (n = 19)
Patients with arterial 
hypertension (n = 30)
p value
Dyslipidaemia 9 (47.4%) 13 (43.3%) 0.51
LDL-cholesterol level [mg/dL] 103.9 ± 34.7 112.3 ± 53.4 0.94
Smoking 9 (47.4%) 12 (40.0%) 0.42
Overweight 8 (42.1%) 9 (30.0%) 0.29
BMI [kg/m2] 25.9 ± 6.1 24.7 ± 5.8 0.13
Vitamin D deficiency [≤ 20 ng/mL] 12 (63.2%) 13 (68.4%) 0.049
Vitamin D level [ng/mL] 13.1 ± 4.2 19.1 ± 10.9 0.69
Figure 2. Prevalence of dyslipidaemia according to the vitamin D levels
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was performed to establish if vitamin D supplemen-
tation (2000 IU/day) reduces BP during 6 months. 
The study included 126 patients, all of whom re-
ceived nifedipine. Reduction of BP and increase in 
25(OH)D blood level was registered. The biggest 
reduction of BP was noticed in patients who had 
vitamin D deficiency, which suggests that vitamin D 
supplementation plays bigger role in patients with 
hypertension and vitamin D deficiency [18]. Ano-
ther trial confirming above conclusion was run in Iran, 
where 8-week, randomized placebo-controlled trial 
took place. After 8 weeks of vitamin D supplemen-
tation its level raised and BP lowered significantly in 
hypertensive population [19]. The weakness of both 
mentioned trials was that all the patients were treated 
with antihypertensive drug, which might have co-
vered 25(OH)D effect.
However there were also trials that showed no 
effect of vitamin D supplementation on BP. One 
of them was performed by Arora et al. The authors 
enrolled population of 534 patients aged between 
18 and 50 with vitamin D deficiency, but only 28% 
of them were hypertensive [20]. The strength of this 
trial was that the patients didn’t take antihypertensive 
drug, but on the other hand, the patients were young 
and mostly normotensive. Six-month supplementa-
tion of vitamin D failed to reduce BP. That leads to 
conclusion that vitamin D supplementation plays 
bigger role in patients with HTN.
The trial that focused on women only, just like 
ours, was the Woman’s Health Initiative. The differ-
ence between these trials was the patients’ age: our 
patients were younger. The authors enrolled popu-
lation of 36 282 postmenopausal woman. Supple-
mentation of vitamin D and calcium didn’t result in 
decreased number of hypertensive patients [21]. The 
weakness of this study was that patients received very 
low vitamin D dose (400 IU/day), which could result 
in increasing 25(OH)D blood level only by 2 ng/mL. 
The dose for vitamin D supplementation remains 
debated, with recommendations varying by coun-
try, usually oscillating around 1000 IU/day [22]. 
The most similar trial to ours, with population of 
1484 non-obese, young women (median age was 43) 
without hypertension suggested that lower plasma 
25(OH)D levels are independently associated with 
a higher risk of incident hypertension [23]. Those 
results match with our outcome. 
The inverse association between 25(OH)D plasma 
level and HTN may be explained by the fact that 
vitamin D is an excellent marker of good health, 
being connected with healthy lifestyle, young age 
and normal body weight [24]. Others claim that 
vitamin D inhibits renin expression [25, 26]. Ad-
ditional pathway of vitamin D lowering BP may be 
connected with parathyroid hormone (PTH). PTH 
is connected with increased BP, myocardial hypertro-
phy and ventricular arrhythmias [23]. Secretion of 
PTH is inhibited by vitamin D [27]. What is more, 
expression of 1a-hydroxylase can be downregulated 
by PTH [27]. This leads to the conclusion that there 
is a feedback loop between vitamin D metabolism 
and PTH. Of course, to discuss all the additional 
findings and suggestions of the pathogenesis another 
article would be needed. 
Conclusion
Connection between vitamin D deficiency and 
hypertension has been raised in many trials result-
ing in mixed outcomes, with advantage of the ones 
suggesting clear connection of HTN with 25(OH)
D serum level. Additionally, the association between 
vitamin D deficiency and HTN is still unknown. 
That is why discussed issue requires more and much 
bigger clinical trials to understand it better. However, 
our trial suggests how important supplementation of 
vitamin D may be in the group of high cardiovascu-
lar risk woman. 
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